🔎 Trials Near Me

홈 › 흑색종 › 콜로라도

콜로라도의 흑색종 임상 시험

흑색종 관련 연구 32개가 콜로라도 내 여러 지역에서 참여자를 모집하고 있습니다.

콜로라도의 도시

공식 연구 텍스트(영어)

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

  • Presbyterian/St Lukes Medical Center, Denver
  • Sarah Cannon Research Institute at HealthONE, Denver
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07519655

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  • Rocky Mountain Regional VA Medical Center, Aurora
  • University of Colorado Cancer Center, Aurora
  • The Melanoma And Skin Cancer Institute, Englewood
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06246916

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  • UCHealth Memorial Hospital Central, Colorado Springs
  • Memorial Hospital North, Colorado Springs
  • Poudre Valley Hospital, Fort Collins
  • 외 3개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05136196

DESTINY-PANTUMOUR04

  • Research Site, Boulder
피험자 모집 중관찰 연구
18세 ~ 130세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07124000

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  • University of Colorado Cancer Center, Aurora
피험자 모집 중3상
18세 ~ 70세 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT05727904

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  • UCHealth University of Colorado Hospital, Aurora
  • Penrose-Saint Francis Healthcare, Colorado Springs
  • Rocky Mountain Cancer Centers-Penrose, Colorado Springs
  • 외 7개
피험자 모집 중3상
75세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT07068074

Pan-tumor MRD Study

  • The Melanoma and Skin Cancer Institute, Englewood
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06605404

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

  • Sarah Cannon Research Institute, Denver
피험자 모집 중1상
18세 ~ 80세 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06398418

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  • Local Institution - 0182, Aurora
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT07492680

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • Rocky Mountain Cancer Centers-Aurora, Aurora
  • University of Colorado Hospital, Aurora
  • Boulder Community Foothills Hospital, Boulder
  • 외 15개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04511013

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • University of Colorado, Aurora
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT05059444

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  • Skin Cancer Institute, Englewood
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07287917

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Rocky Mountain Regional VA Medical Center, Aurora
  • UCHealth University of Colorado Hospital, Aurora
  • Penrose-Saint Francis Healthcare, Colorado Springs
  • 외 15개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT05334069

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

  • Sarah Cannon Research Institute Denver, Denver
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT04913285

Project: Every Child for Younger Patients With Cancer

  • Children's Hospital Colorado, Aurora
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
피험자 모집 중관찰 연구
25세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT02402244

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's Hospital Colorado, Aurora
피험자 모집 중1/2상
12 Months – 30 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04851119

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

  • University of Colorado Hospital, Aurora
피험자 모집 중
55세 이상 · 모든 성별 · 2026. 8. 7. 업데이트됨 · NCT07704918

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  • Call for Information (Investigational Site 0019), Aurora
피험자 모집 중1/2상
6 Months – 17 Years · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT02332668

Integrated Cancer Repository for Cancer Research

  • Advent Health, Greenwood Village
피험자 모집 중관찰 연구건강한 지원자 환영
19세 ~ 110세 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT02012699

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

  • SCRI Oncology Partners- Denver, Denver
피험자 모집 중1/2상
18세 ~ 70세 · 모든 성별 · 2026. 6. 15. 업데이트됨 · NCT06940739

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

  • SCRI - Denver, Denver
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 8. 업데이트됨 · NCT03947385

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA01-0, Wheat Ridge
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 22. 업데이트됨 · NCT06953089

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

  • University of Colorado, Anschutz Medical Campus, Aurora
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 5. 13. 업데이트됨 · NCT03686124

Neoadjuvant Darovasertib in Primary Uveal Melanoma

  • University of Colorado Hospital, Aurora
  • The Melanoma and Skin Cancer Institute, Englewood
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 5. 6. 업데이트됨 · NCT07015190

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

  • University of Colorado Anschutz, Aurora
  • University of Colorado, Denver
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT06624644

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

  • Sarah Cannon Research Institute at Health ONE, Denver
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 20. 업데이트됨 · NCT06326411

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

  • University of Colorado Cancer Center, Aurora
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 13. 업데이트됨 · NCT06362369

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  • University of Colorado Hospital - Anschutz Cancer Pavilion(ACP), Aurora
  • The Melanoma & Skin Cancer Institute, Englewood
피험자 모집 중2/3상
전 연령 · 모든 성별 · 2026. 4. 2. 업데이트됨 · NCT06581406

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Rocky Mountain Cancer Centers-Aurora, Aurora
  • Rocky Mountain Cancer Centers-Boulder, Boulder
  • Rocky Mountain Cancer Centers - Centennial, Centennial
  • 외 12개
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 3. 17. 업데이트됨 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Aurora
  • Massive Bio SYNERGY-AI site, Denver
  • Massive Bio SYNERGY-AI site, Littleton
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

  • HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE, Denver
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 2. 13. 업데이트됨 · NCT05669430

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

  • Sarah Cannon Research Institute at HealthONE, Denver
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2024. 11. 15. 업데이트됨 · NCT04787042

ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.